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Cell surface-associated proteases are involved in many physiolog-
ical processes ranging from morphogenesis and tissue differentia-
tion to the general regulation of haemostasis. Apart from their role
in terminal degradation of proteins and regulation of hormone
levels, some of these enzymes appear to be functionally involved
in cell activation (Fleisher, 1994; Bauvois, 1997; Letarte et al,
1997). Of these ectoenzymes, the serine ectoprotease dipep-
tidylpeptidase IV (DPP IV) (EC 3.4.14.5) identical to CD26
antigen, has been shown to be a marker for T lymphocyte activa-
tion (Fleisher, 1994). CD26/DPP IV is associated with the protein
tyrosine phosphatase CD45, and at the level of its extracellular
domain with adenosine deaminase-1 (ADA-1), the lack of which is
associated with severe combined immunodeficiency (Fleisher,
1994). CD26/DPP IV is abundantly expressed in kidney, lung,
small intestine and liver (Fleisher, 1994). In the immune system,
CD26/DPP IV is found primarily at low density on subsets of
CD4+ and CD8+ T-cells and on CD3+ medullary thymocytes
(Fleisher, 1994) and on activated natural killer (NK) and B-cells
(B￿hling et al, 1994; Fleisher 1994).
Enzyme cytochemical and/or immunophenotypic approaches
of CD26/DPP IV suggested this enzyme to be a useful marker in
some pathologies. Overexpression of CD26/DPP IV was
observed in differentiated thyroid carcinomas (Tanaka et al,
1995) and on T blood cells from patients with autoimmune
diseases including progressive multiple sclerosis, Graves￿
disease and rheumatoid arthritis (Hafler et al, 1985; Eguchi et al,
1989; Nakao et al, 1989). In contrast, the loss of CD26/DPP IV
molecule from the surface of T-cells has been associated with T-
CLL (chronic lymphocytic leukaemia) and ALL (acute lympho-
cytic leukaemia) diseases (Kondo et al, 1996), oral cancer
(Uematsu et al, 1996) and HIV infection (Vanham et al, 1993).
CD26/DPP IV expression in human lymphomas appeared to be
restricted to CD30+ anaplastic large cells (irrespective of their
T/B phenotype) and to a subset of non-Hodgkin￿s T-cells
whereas non-Hodgkin￿s B-cells did not express CD26 antigen
(Carbone et al, 1994). Conflicting data were, however, reported
with the detection of a high DPP IV activity in B-cell lysates
from patients with non-Hodgkin￿s lymphoma when compared
with those from normal individuals (Khalaf et al, 1987).
Moreover, attempts have been made to correlate the expression
of DPP IV with B-CLL, with controversial results. Indeed, some
studies demonstrated the presence of low but detectable levels of
DPP IV activity in lysates of B-CLL cells (Feller et al, 1983;
Srivastava and Bhargava, 1986; Scott et al, 1988) or on intact B-
CLL cells (Bylinka et al, 1992). In contrast, two cytochemical
studies indicated that B-CLL cells failed to express a DPP IV
activity (Andrews et al, 1985; Invernizzi et al, 1985).
The objective of this study was to assess the expression of
CD26/DPP IV molecules on the surface of lymphocytes of B-CLL
patients in comparison with that of healthy subjects. We show here
a clear correlation between B-CLL malignancy and CD26/DPP IV
cell surface expression that might be implicated in the regulation
of lymphocyte proliferation.
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Summary We have investigated the expression of the ectoenzyme dipeptidylpeptidase IV (DPP IV)/CD26 on lymphocytes obtained from
patients with B chronic lymphocytic leukaemia (B-CLL) and compared it with healthy subjects. Using two-colour immunofluorescence analysis
with CD26 and CD20 or CD23 monoclonal antibodies, CD26 was found undetectable on peripheral resting B-cells (CD20+ CD23–) from
normal donors whereas it was expressed on B-cells activated in vitro with interleukin (IL)-4 and Staphylococcus aureus strain cowan I (CD20+
CD23+). The expression of CD26 on leukaemic B-cells (CD20+ CD23+) was clearly induced in 22 out of 25 patients examined. Consequently,
induced levels of CD26 cell surface expression on either normal activated and malignant B-cells coincided with the enhancement of DPP IV
activity detected on the surface of these cells. Reverse transcription polymerase chain reaction analyses showed that the transcript levels of
the CD26 gene was higher in normal activated B-cells and B-CLL cells than in resting B-cells, suggesting that CD26 was expressed at the
level of transcriptional activation. These observations provide evidence of the abnormal expression of DPPIV/CD26 in B-CLL which,
therefore, may be considered as a novel marker for B-CLL. Further investigation in relation to CD26 expression and other B malignancies
needs to be defined.
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Antibodies and reagents
Rhodormine (RD)-conjugated CD26 (Ta1, mIgG1) monoclonal
antibody (mAb), RD-conjugated mouse IgG1 (mIgG1), fluorescein
isothiocyanate (FITC)-conjugated mIgG1 and mIgG2a were
obtained from Coulter (USA). FITC-conjugated —CD20 (B9E9,
mIgG2a), —CD3 (´35, mIgG2a), —CD23 (9P.25, mIgG1), —CD5
(BL1a, mIgG2a) and FITC-conjugated CD14 (RM052, mIgG2a)
were from Immunotech (Marseille, France). Magnetic beads coated
with CD19+ were purchased from Dynal (Oslo, Norway). TA5.9
mAb directed against CD26 (mIgG1) was characterized previously
(De Meester et al, 1993). Ficoll-Hypaque was purchased from
Pharmacia (Uppsala, Sweden). Staphylococcus aureus strain cowan
I (SAC) was obtained from Clini-Sciences (Montrouge, France).
Recombinant human interleukin-4 (rIL-4) was purchased from
Immugenex (Los Angeles, CA, USA; sp. act.: 108 U mg—1). Gly-
Pro-p-nitroanilide (pNA) was purchased from Sigma Chemical Co.
(St Louis, MO, USA).
Cells
Human mononuclear cells were isolated from heparinized normal
peripheral blood by Ficoll-Hypaque (Pharmacia) density gradient
centrifugation. B-cells were isolated using beads coated with
Abs to CD19 and detached with Detachabeads (Dynal) and the
B-enriched population contained † 5% CD3+ and † 5% CD14+
cells. B-cell cultures were performed in flat-bottomed 24-well
microtiter with each well containing purified B-cells (1 ´ 106) in
1 ml of Roswell Park Memorial Institute (RPMI)-1640 medium
plus 5% fetal calf serum (FCS), containing 2 mM glutamine and
10 mg ml—1 gentamycin. Some cell cultures were stimulated with
rIL-4 (100 U ml—1) or SAC (0.01%) or combinations of rIL-4 plus
SAC, at 37°C for 2 days in a humidified atmosphere containing
5% carbon dioxide. Untreated patients (25) with B-CLL (17 males
and eight females) were included in the study. B-CLL diagnosis
was established according to the international CLL workshop
criteria including peripheral blood lymphocyte morphology and
coexpression of CD5, CD20 and CD23 antigens.
Flow cytometry analysis
Cells were immunostained as previously described (Bauvois et al,
1996). Analysis was performed on a FACS flow cytometer
analyser (Becton-Dickinson, Mountain View, CA, USA); 10 000
events were recorded and analysed using the Lysys software
(Becton Dickinson). Fluorescence data were expressed in relative
fluorescence intensity (%) and antigen relative density per cell
was obtained by subtracting the peak channel number of the nega-
tive control from the peak channel number of the corresponding
experimental sample.
DPP IV activity assay
DPP IV activity at the surface of intact cells was measured spec-
trophotometrically by hydrolysis of Gly-Pro-pNA and formation
of pNA, as previously described (Bauvois et al, 1992).
RNA extraction and RT-PCR
Total RNA was prepared by acid guanidinium thiocyanate—
phenol—chloroform extraction from cells (Chomeczynski and
Sacchi, 1987). A 0.5 mg total RNA was reverse transcribed with
0.2 mg random hexamers (Boehringer, Vienna, Austria) in the
presence of 200 U Moloney murine leukaemia reverse trancriptase
(RT; BRL, Meylan, France). CD26 cDNA was amplified using the
sense primer 5¢-ATG GAC GGG GAA AGA AGA TA-3¢ corre-
sponding to bases 568—587 of the human cDNA sequence (Abbott
et al, 1994) and the antisense primer 5¢-TTT ACA GTT GGA TTC
ACA GCT C-3¢ corresponding to bases 789—810, to generate a
223-bp product. b2-microglobulin cDNA was amplified using the
sense primer 5¢- CAT CCA GCG TAC TCC AAA GA-3¢ and anti-
sense 5¢-GAC AAG TCT GAA TGC TCC AC-3¢ to generate a
165-bp product. The polymerase chain reaction (PCR) mixture
comprised 50 ng template cDNA, 67 mM Tris-HCl (pH 8.8),
16.6 mM ammonium sulphate ((NH4)2SO4), 2.7 mM magnesium
chloride, 1 mM dNTP, 0.5 mM of each primer and 1.25 U Taq poly-
merase (Boehringer, Vienna, Austria) in a total volume of 100 ml.
Reactions were performed in DNA thermal cycler (Perkin Elmer)
with 35 cycles of 94°C for 50 s (denaturation), 57°C for 50 s
(annealing) and 72°C for 20 s (elongation). In all experiments, a
free blank was tested as a check for contamination. The PCR prod-
ucts were first visualized by electrophoresis in 2% agarose gel
containing 0.2 mg ml—1 ethidium bromide. For final detection, the
PCR products were separated on 7% polyacrylamide gels and
visualized using ethidium bromide.
RESULTS AND DISCUSSION
Differential expression of CD26 molecules on the
surface of B-CLL and control group (resting and
activated) B-cells
By using one-colour FACS analysis, it was previously suggested that
a small subset († 5%) of normal peripheral B-cells reacted with the
mAb Ta1 raised against the CD26 molecule from activated T-cells
(B￿hling et al, 1994). In this study, two-colour FACS analysis was
used to determine the levels of Ta1/CD26 expression on CD20+ B-
cells. We identified on peripheral blood lymphocytes (PBL) cells
from normal healthy donors, a CD20+ B-cell population negative for
Ta1/CD26 (Figure 1.3). Following cell isolation, purified CD20+ B-
cells were unreactive with CD26/Ta1 mAb (Figure 1.6) and with
CD23 mAb (data not shown). As illustrated in Figure 2, isolated
CD20+CD23—B-cells from seven healthy donors were found CD26—.
B￿hling et al (1994) previously found that SAC increased CD26
expression on B-cells. Moreover, the physiological B-cell stimula-
tory factor IL-4 is known to increase the expression of a variety of
molecules on B-cells including CD23 (Kolb et al, 1991). Thus,
resting CD20+CD23—CD26—B cells were in vitro cultured for 2 days
in the absence or in the presence of rIL-4 or SAC, or combinations of
rIL-4 and SAC. Our study confirmed the enhancing effect of SAC
and revealed new findings with regard to its association with IL-4.
When co-stained with CD23 and CD26/Ta1 mAbs, most of rIL-4-
stimulated B-cells showed expression of CD23 antigen (Figure 3.6)
whereas SAC-stimulated B-cells showed increase in CD26 expres-
sion (Figure 3.9). Combination of rIL-4 and SAC stimulation
resulted in two subpopulations of activated B-cells, one subpopula-
tion CD23+ CD26— and the other CD23+ CD26+ (Figure 3.12).
Analysis of the results obtained from four separate experiments indi-
cate that 20—50% activated B-cells were CD23+ CD26+ (Figure 2).
When CD26 expression was investigated in 25 cases of B-CLL
(positive for CD5, CD20 and CD23), three cases were found nega-
tive for CD26/Ta1 whereas 22 cases displayed a very moderate to
Abnormal expression of CD26/DPP IV in B-CLL 1043
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Figure 1 Representative cytograms of normal B and leukaemic B-CLL cells costained with CD26 and CD20 mAbs. PBMC cells and isolated B-cells from one
normal donor, and B-cells from two B-CLL patients obtained as described in Material and methods, were examined by two-colour immunofluorescence staining
in flow cytometry analysis. Cells were stained with CD20-FITC/mIgG1-RD (1, 4, 7, 10) or mIgG2a-FITC/Ta1-RD (2, 5, 8, 11) or CD20-FITC/Ta1-RD (3, 6, 9, 12).
The x-axis shows log green fluorescence and the y-axis shows red fluorescence. Quadrants delineated by squares indicate negative and positive populations of
cells as determined using negative controls (1 and 2, 4 and 5, 7 and 8, 10 and 11)Abnormal expression of CD26/DPP IV in B-CLL 1045
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strong staining of cell surface CD26 (from 5 to 70% positive cells,
Figure 2). Representative positive- and negative-CD26 FACS
cytograms of cells from two patients, stained with CD20 and
CD26 mAbs, are presented in Figure 1.9 and 1.12, respectively. It
was noted that CD26/TA5.9 mAb similarly detected CD26 anti-
gens on activated B-cells (data not shown).
To determine whether the differences observed in cell surface
CD26 expression from normal (activated vs resting) and
leukaemic B-cells, could be accounted for by the abundance of
CD26 mRNA, RT-PCR experiments were carried out on total
mRNA extracted from various B-cell populations. As shown in
Figure 4, samples were standardized for total cDNA content by
assessing the presence of identical amounts of b2-microglobulin
transcript. As controls, the expected 223-bp CD26 product was
observed in activated T-cells and human dermal fibroblasts,
respectively (Figure 4, lanes 12 and 13). As shown in Figure 4, the
223-bp-specific band was detected at very low levels in resting
CD26— B-cells from three donors (lanes 1—3) whereas an increased
CD26 signal was found in CD23+-activated B-cells (lane 4
compared to lane 3) and in five B-CLL samples (lanes 6, 8—11)
positive for CD26 cell surface expression. Thus, it appears that
CD26 mRNA was increased in CD23+ B-cells and that this
increase was followed by an induction of CD26 molecules at the
surface of these cells.
Cell surface CD26 up-regulation is correlated with an
increase in cell surface DPP IV activity
The CD26 molecule is identical to the serine ectoprotease DPP IV
(Fleisher, 1994). DPP IV activity is usually assessed by measuring
the rate of hydrolysis of the chromogenic substrate Gly-Pro-pNA
and inhibition of the cleavage by specific inhibitors of DPP IV
activity (DFP, diprotin A) (Bauvois et al, 1992). We therefore
investigated Gly-Pro-pNA hydrolysis by normal resting and
activated B-cells and B-CLL cells. With resting B-cells, a basal
activity was detected (< 200 pmole/30 min/105 cells, Figure 5).
After IL-4/SAC treatment, DPP IV activity was markedly
increased by a factor of 2—3 and this stimulation paralleled the
increase in CD26 expression we observed under the same condi-
tions (Figure 5). When 17 B-CLL cells were co-analysed for CD26
expression and DPP IV activity, a significant correlation was also
found between DPP IV activity and CD26 expression determined
as the per cent of positive cells (Figure 5). A similar correlation
was obtained between DPP IV activity and the number of CD26
molecules displayed by individual cells (relative amount of
antigen density per cell, data not shown). Together, these results
suggest that up-regulated levels of DPP IV activity on CD23+ cells
were attributable to the induction of CD26.
CONCLUSION
In this study, we have investigated CD26/DPP IV expression in
B lymphocytes from normal adults and compared with their
neoplastic counterpart B-cells from patients with B-CLL. B-CLL
represents a chronic lymphoproliferative disorder with a high
biological and clinical heterogeneity. We found that normal
peripheral CD23— B-cells from healthy donors are negative for cell
surface CD26. When B lymphocytes become in vitro activated
with IL-4 and SAC, the expression of CD26 was induced on
CD23+ B-cells. Our major finding concerns the constitutive
expression of CD26 on CD23+ cells from a majority of untreated
patients with B-CLL (88%). RT-PCR analyses suggest that CD26
up-regulation was at the level of transcription activation. Recently,
two additional forms of DPP IV have been characterized on T
lineage cells (Duke-Cohan et al, 1996; Jacotot et al, 1996); both
expressed DPP IV activity but were incapable of binding ADA-1
(Duke-Cohan et al, 1996; Jacotot et al, 1996). Additionally, a DPP
IV protein closely related to DPP IV but without DPP IV activity
has also been described (Yokotani et al, 1993). In our study, we
found that the degree of Ta1/CD26 expression was in good corre-
lation with the levels of DPP IV enzymatic activity, and that DPP
IV activity was indeed attributable to the CD26 form endowed
with the capacity to bind ADA (data not shown). Thus, our data
suggest that malignant B-cells, like activated normal B-cells,
express at their surface a CD26/DPP IV molecule similar to the
major form of CD26/DPP IV present on activated T-cells. In vitro
treatment of activated T- and B-cells with specific DPP IV
inhibitors led to cell growth suppression and a decrease in
cytokine or IgM production (Sch￿n et al, 1987; Flentke et al, 1991;
B￿hling et al, 1994). A specific inhibitor of DPP IV prodipine has
recently been shown to abrogate in vivo systemic IgM allo-Ab
responses in rats (De Meester et al, 1997). With regard to T-cells,
the 105 kDa CD26 molecule has a direct stimulatory function for
T-cell proliferation and is able to transduce strong comitogenic
signals through the same signal transduction pathways involved in
T-cell activation via the CD3 complex (Fleisher, 1994; Hegen et al,
1997). Alternatively, it cannot be excluded that CD26/DPP IV,
based on its enzymatic properties, functions to regulate cell growth
through the activation/inactivation of crucial factors (Fleisher,
1994). Finally, with regard to its binding capacity to extracellular
matrix components including collagens and fibronectin (Fleisher,
1994), CD26/DPP IV could enhance the invasive properties of
tumour cells from bone into blood. Further investigation is there-
fore required to clarify the role, if any, of B-cell CD26 in the
control of cell proliferation in leukaemia.
Concomitantly with the overexpression of CD26/DPP IV on
B-CLL cells, we have recently observed significant higher levels
of DPP IV activity (up to threefold) in sera from B-CLL patients as
compared to normal sera (B Bauvois, unpublished results).
Although DPP IV activity in serum may be released from
various types of cells (Fleisher, 1994; Duke-Cohan et al, 1996),
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the possibility that soluble DPP IV activity originates from
leukaemic B-cells is now under investigation.
In conclusion, the present study shows that B-CLL is associated
with abnormal expression of plasma membrane CD26/DPP IV and
suggests that this novel marker may have additional value in moni-
toring patients with other B-cell malignancies.
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